Related by context. All words. (Click for frequent words.) 76 mouse xenograft models 74 demonstrated antitumor activity 73 ENMD # 72 EGFR HER2 72 anti leukemic 72 preclinical xenograft models 72 CYT# potent vascular disrupting 72 cisplatin resistant 71 antitumor activity 71 xenografts 71 tumor regressions 71 tumor xenograft models 71 trastuzumab Herceptin R 71 induces apoptosis 71 potent antitumor activity 70 ovarian carcinoma 70 pegylated liposomal doxorubicin 70 imatinib Gleevec ® 70 5 FU leucovorin 70 antisense inhibition 70 receptor tyrosine kinase inhibitor 70 lenalidomide dexamethasone 70 pathophysiological effects 70 potent inhibition 70 antiangiogenic activity 70 epithelial tumors 70 CA4P 70 Seliciclib 70 gemcitabine Gemzar 70 poly ADP ribose polymerase 70 cMET 70 xenograft tumors 70 anti CD3 70 erlotinib Tarceva ® 69 anti fibrotic 69 HER2 overexpression 69 vitro cytotoxicity 69 depsipeptide 69 relapsed MM 69 microtubule targeting 69 HSP# inhibitor 69 Symadex 69 selective inhibition 69 nanomolar 69 pan HDAC inhibitor 69 antiproliferative effects 69 thalidomide Thalomid 69 targeting CD# 69 milatuzumab 69 orthotopic model 69 syngeneic 69 XL# inhibits 69 liposomal formulation 69 TRAIL induced apoptosis 69 interferon IFN 69 pomalidomide 69 fosbretabulin 69 TRAIL R1 69 AAG geldanamycin analog 69 VEGFR2 69 orally administered inhibitor 69 OXi# 69 inhibitory effects 69 immunohistochemical staining 69 imatinib Gleevec 68 mTOR inhibitors 68 dasatinib Sprycel 68 CDK inhibitor 68 Bezielle 68 OMP #M# 68 gemcitabine carboplatin 68 Gleevec resistant 68 ganetespib 68 selective kinase inhibitor 68 radiochemotherapy 68 ErbB2 positive 68 effector function 68 potent cytotoxic 68 TRAIL R2 68 Flt3 68 PKC# 68 oral JAK1 68 antiangiogenic agents 68 ON #.Na 68 tumor xenografts 68 pro apoptotic 68 sorafenib Nexavar ® 68 orthotopic 68 bevacizumab Avastin R 68 HER2 positive metastatic breast 68 c MET 68 antitumor effects 68 histone deacetylase inhibitor 68 Anthracycline 68 sorafenib Nexavar 68 Omacetaxine 68 JAK inhibitors 68 HGS ETR1 mapatumumab 68 colon carcinoma 68 LHRH receptor positive 68 imetelstat 68 HGS ETR2 68 trastuzumab Herceptin ® 68 bendamustine 68 GMX# 68 etoposide 67 anti proliferative 67 pancreatic adenocarcinoma 67 #ME# 67 IAP inhibitor 67 ERK1 2 67 IGF 1R 67 orally bioavailable 67 molecularly targeted 67 vinca alkaloid 67 LHRH antagonists 67 Carfilzomib 67 cytotoxicity 67 busulfan 67 gefitinib Iressa 67 alvespimycin 67 transgene expression 67 preclinical efficacy 67 liposomal doxorubicin 67 antitumor efficacy 67 potently inhibited 67 nucleoside analog 67 estramustine 67 evaluating tivozanib 67 c MYC 67 potent antiproliferative 67 Factor Receptor 67 oral prodrug 67 viral kinetics 67 induce apoptosis 67 K ras mutations 67 papillary renal cell carcinoma 67 vidofludimus 67 sunitinib Sutent ® 67 azacytidine 67 somatostatin 67 selective modulator 67 peripheral blood mononuclear 67 heavily pretreated patients 67 Blinatumomab 67 selective inhibitor 67 hA# 67 potent inhibitor 67 paclitaxel Taxol ® 67 FGFR 67 androgen independent 67 heavily pretreated 67 potently inhibit 67 CCR9 67 antiangiogenic therapy 67 daunorubicin 67 radiation sensitizer 67 histologies 67 immune modulating 67 antimitotic 67 mRNA expression 67 Xanafide 67 MEK inhibitors 67 PI3K inhibitor 67 CD# expressing 67 gemcitabine cisplatin 67 MAPK pathway 67 seliciclib 67 HCV replicon 67 tumorigenicity 67 HCV protease 67 tumor regression 67 vivo efficacy 67 HGS# 67 delafloxacin 67 pharmacodynamic PD 67 TTR gene 67 HepG2 cells 67 IFN α 67 neurotrophic 67 immune stimulatory 67 Upregulation 67 induced tumor regression 67 antitumor 67 cytoprotective 66 MGd 66 PI3K Akt 66 AKT inhibitor 66 selective agonist 66 immunomodulating 66 antiapoptotic 66 synthase TS 66 APOPTONE 66 xenograft model 66 neratinib 66 human tumor xenografts 66 pleiotropic 66 protein kinase inhibitor 66 INGN 66 topoisomerase II inhibitor 66 flavopiridol 66 factor HGF 66 BAL# [001] 66 TGF beta1 66 sunitinib malate 66 preclinically 66 xenograft 66 Neulasta ® 66 receptor inhibitor 66 TIMP 1 66 Fludara ® 66 xenograft tumor models 66 immunomodulatory 66 pharmacokinetic interactions 66 panobinostat 66 Doxil ® 66 bevacizumab Avastin ® 66 polycythemia vera PV 66 paclitaxel Taxol 66 inhibited tumor 66 ritonavir boosted 66 TNFalpha 66 HER2 positive cancers 66 M1 muscarinic 66 nanomolar potency 66 signal transduction inhibitor 66 hepatoma 66 selectively inhibits 66 proteasome inhibitor 66 standard chemotherapy regimens 66 PI3K/mTOR 66 V#F mutation 66 huN# DM1 66 doxorubicin cyclophosphamide 66 Hsp# inhibition 66 docetaxel Taxotere ® 66 TO AVOID PREGNANCY WHILE 66 immunomodulator 66 CD# antibody [001] 66 trabectedin 66 Aplidin 66 taxane resistant 66 reversible inhibitor 66 decitabine 66 bortezomib Velcade 66 lung carcinomas 66 galiximab 66 docetaxel chemotherapy 66 sarcoma melanoma 66 HGS ETR1 66 potent inhibitory 66 FLT3 66 Antitumor Activity 66 TRAIL receptors 66 novel VDA molecule 66 cisplatin carboplatin 66 pro angiogenic 66 imatinib resistant 66 KRAS mutations 66 ERBB2 66 demethylating agent 66 interleukin IL -# 66 erythropoietic 66 Smac mimetics 66 targeted antifolate 66 tumor necrosis 66 CTAP# Capsules 66 EGFR mutant 66 kinase inhibitor 66 adriamycin 66 NS5B polymerase 66 lenalidomide Revlimid R 66 Voreloxin 66 alkylating agent 66 Angiolix 66 Vidaza ® 66 EpCAM 66 cyclin E 66 bleomycin 66 IL 1ß 66 kinase inhibition 66 murine model 66 cisplatin gemcitabine 66 nilotinib Tasigna ® 66 ara C 66 PSMA ADC 66 plasma kallikrein inhibitor 66 mutated KRAS 66 hypereosinophilic syndrome 66 estrogen receptor beta 66 EGFR tyrosine kinase inhibitors 66 #F FDG PET 66 antiangiogenic 66 PXD# 66 EGFRvIII 66 preclinical models 66 pDCs 66 Interferon alfa 66 taxane therapy 66 proteasome inhibitors 65 Interferon alpha 65 MET amplification 65 novel peptide 65 multi kinase inhibitor 65 pancreatic prostate 65 mTOR inhibition 65 IL 1Ra 65 enzastaurin 65 LHRH agonists 65 promoter methylation 65 retaspimycin 65 pharmacodynamic markers 65 Aurora kinase 65 Imprime PGG 65 inhibiting tumor 65 colorectal carcinoma 65 anti amnesic 65 Thiarabine 65 pancreatic colon 65 vitro experiments 65 SERMs 65 hypoxia inducible factor 65 microtubule inhibitor 65 solithromycin 65 KRAS mutant 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 Tarceva TM 65 recurrent glioblastoma multiforme 65 PC# cells 65 bone metastasis 65 Erlotinib 65 Platinol ® cisplatin 65 antisense inhibitors 65 RRM1 65 Onconase 65 fluoropyrimidine 65 chemotherapeutic regimens 65 oral chemotherapeutic agent 65 sorafenib tablets 65 VEGF receptor 65 MetMAb 65 GRN#L 65 anticancer activity 65 hematological tumors 65 potently inhibits 65 tubulin inhibitor 65 Fc fusion protein 65 tyrosine kinase inhibitor 65 dexamethasone Decadron 65 FUSILEV enhances 65 multitargeted 65 nucleoside analogues 65 metabolomic profiles 65 liver metastasis 65 trans retinoic acid 65 Preclinical studies 65 DNA methyltransferase inhibitors 65 IGF IR 65 nucleotide analogs 65 5FU 65 immunomodulation 65 alpha folate receptor 65 locoregional recurrence 65 5 HT6 receptor 65 Cyclin E 65 bronchial epithelial cells 65 Hsp# Inhibitor 65 lymphoma subtypes 65 lymphoid malignancies 65 sulfasalazine 65 tigecycline 65 gemcitabine Gemzar ® 65 Mutational 65 PARP inhibition 65 neoadjuvant 65 chemotherapeutic agents 65 Etoposide 65 cyclin dependent kinases CDKs 65 mGluR2 NAM 65 dasatinib Sprycel ® 65 antitumor effect 65 VEGF inhibitors 65 EGFr 65 CHOP chemotherapy 65 myeloproliferative diseases 65 mTOR mammalian target 65 ERalpha 65 mda 7 65 Vidofludimus 65 neutralizing antibody responses 65 LPS induced 65 chemotherapeutic drug 65 protein tyrosine phosphatase 1B 65 UsiRNAs 65 prognostic indicator 65 E#F# 65 uricase 65 favorable pharmacokinetic profile 65 TNF α 65 colorectal adenocarcinoma 65 selective antagonist 65 tumor subtypes 65 histone deacetylase HDAC inhibitor 65 splice variants 65 haematopoietic 65 vascular disrupting agents 65 myeloproliferative disorders 65 Trastuzumab 65 Diffuse Large B 65 irreversible inhibitor 65 secretory phospholipase A2 sPLA2 65 immunostimulatory 65 mutational status 65 breast carcinomas 65 systemically administered 65 NFκB 65 lymphoid cells 65 2 methoxyestradiol 65 bortezomib Velcade R 65 oncogenic transformation 65 combinability 65 SSc 65 Pharmacokinetics PK 65 mycophenolate mofetil 65 nab paclitaxel 65 SCCHN 65 breast cancer subtypes 65 humoral immune responses 65 alfa 2a 65 antiandrogens 65 TLR9 agonists 65 EZN 65 vinca alkaloids 65 rhIGFBP 3 65 T#I [002] 65 Epidermal Growth Factor Receptor 65 Kinase Inhibitor 65 EGFR TKIs 65 kidney urologic 65 proto oncogene 65 HER2 HER2 65 Epothilones 65 cytokine refractory 65 prostate carcinoma 65 interferon alfa 2b 65 axitinib 65 agonistic human 65 cytotoxic 65 chemotherapy FOLFOX 65 OHR/AVR# 65 histologic subtypes 65 geldanamycin 65 experimental autoimmune encephalomyelitis 65 Zalypsis 64 Aurora Kinase 64 rhIL 7 64 HuLuc# 64 nucleotide analog 64 anti angiogenic 64 cytotoxic agents 64 Amrubicin 64 mediated inhibition 64 tyrosine kinase inhibitor TKI 64 chemoradiotherapy 64 HIF 1α 64 Lenocta 64 antiproliferative activity 64 pertuzumab 64 Thiovir 64 YONDELIS 64 metastatic neuroendocrine tumors 64 breast carcinoma 64 EGF receptor 64 IMiDs ® compound 64 TNF alpha selectively neutralizing 64 PI3K/Akt pathway inhibitor 64 CLORETAZINE TM VNP#M 64 AT1R 64 hTERT 64 MDR1 64 Cloretazine R 64 MAGE A3 ASCI 64 Panzem NCD 64 potent suppressor 64 IMC A# 64 skeletal metastases 64 novel histone deacetylase 64 NSCLC tumors 64 lymphoid tumors 64 p# biomarkers 64 peptide antigens 64 HER2 ErbB2 64 Deforolimus 64 intratumoral injection 64 prostanoid 64 nilotinib Tasigna 64 pulmonary metastases 64 cyclophosphamide methotrexate 64 BRAF inhibitor 64 ELACYT 64 ixabepilone 64 proteins peptides 64 potent anti angiogenic 64 isotypes 64 EGFR inhibitors 64 p# inhibitor 64 Enzastaurin 64 bexarotene 64 vivo preclinical studies 64 mapatumumab 64 TLR8 64 immune modulatory 64 TTF Therapy 64 deacetylation 64 inducing apoptosis 64 isoenzyme 64 Raf MEK ERK 64 colorectal pancreatic 64 activin 64 glioblastoma multiforme GBM 64 CCR2 64 AKT1 64 pharmacodynamic profiles 64 p# activation 64 chemotherapeutic 64 FOLFOX6 chemotherapy regimen 64 potentially hepatotoxic 64 letrozole Femara 64 p# mitogen activated 64 antisense compounds 64 lesional 64 anticancer therapies 64 Leydig cell 64 bortezomib Velcade ® 64 FGFR3 64 talabostat 64 IFN beta 64 metastatic renal cell carcinoma 64 refractory chronic lymphocytic 64 surgical debulking 64 melphalan prednisone 64 liposome encapsulated 64 carboplatin paclitaxel 64 cetuximab Erbitux R 64 neoadjuvant chemotherapy 64 oral Hsp# inhibitor 64 PNP inhibitor 64 forodesine 64 pharmacodynamic properties 64 anti EGFR antibody 64 pegfilgrastim 64 anti atherogenic 64 vitro studies 64 Immunohistochemical analysis 64 factor G CSF 64 Capecitabine 64 TNFa 64 radiosensitivity 64 Beta catenin pathway 64 GPx 64 Eg5 64 ligand TRAIL 64 immunoreactivity 64 PDGFR 64 Interferon beta 64 telomerase inhibition 64 ERK signaling 64 triphendiol 64 oncoprotein 64 peptidomimetic 64 HDAC inhibition 64 ZFN modified 64 myelofibrosis polycythemia vera 64 HIF PHI 64 missense mutations 64 paricalcitol 64 pharmacodynamic profile 64 HIF 1alpha 64 PBMCs 64 cilengitide 64 chimeric monoclonal antibody 64 relapsed refractory 64 Cisplatin 64 ectopic expression 64 IFN gamma 64 precursor lesions 64 predictive biomarker 64 fallopian tube cancers 64 essential thrombocythemia ET 64 IFN alpha 64 constitutively expressed 64 NOD SCID mice 64 serine threonine 64 anti angiogenic therapy 64 thrombin receptor 64 Cardiotoxicity 64 MMP2 64 nucleoside analogs 64 PEG SN# 64 Immunohistochemical staining 64 AEG# 64 LNCaP cells 64 cyclin dependent kinase inhibitor 64 CIMZIA ™ 64 chemo resistant 64 PTHrP 64 adecatumumab 64 murine 64 Pemetrexed 64 gastrointestinal stromal tumors GISTs 64 PEGPH# 64 deacetylase 64 CTGF 64 Cloretazine 64 phosphate S1P 64 leukemia AML 64 anti angiogenic agent 64 CCX# 64 transgenic mouse models 64 GHRH 64 Apoptone 64 factor receptor FGFR 64 multikinase inhibitor 64 nucleoside 64 ® bortezomib 64 Xenograft 64 antitumoral 64 FOLFOX chemotherapy 64 Estrogen Receptor 64 idarubicin 64 immunostaining 64 deforolimus 64 JVRS 64 novel anticancer 64 HDACi 64 DFMO 64 SCH # 64 abnormal p# 64 carcinoids 64 survivin 64 colorectal tumor 64 adrenoceptor 64 Clusterin 64 HIF PH inhibitors 64 Janus Kinase 64 vorinostat 64 ovarian lung 64 FGFR2 64 KRAS oncogene 64 p# biomarker 64 picomolar 64 HER1 64 Panzem R NCD 64 eNOS 64 hemagglutination inhibition HAI 64 telomerase reverse transcriptase 64 P selectin 64 JAK#/JAK# 64 CCR1 64 R roscovitine 64 IL 1β 64 conventional chemotherapies 64 vincristine doxorubicin 64 retapamulin 64 CDK4 64 p# alpha [001] 64 antiangiogenesis 64 induced apoptosis 64 recurrent NSCLC 64 cyclooxygenase 2 64 CYC# 64 Pertuzumab 64 immunosuppressive regimens 64 immunotoxin 64 potent inhibitors 64 Fibroblast Growth Factor Receptor 64 NF kB pathway 64 androgen receptor AR 64 APTIVUS r 64 heparanase 64 hepatocellular carcinomas 64 small molecule thrombopoietin 64 carcinoembryonic antigen 64 selective inhibitors 63 paclitaxel cisplatin 63 sarcomatoid 63 humanized monoclonal antibodies 63 distant metastasis 63 temozolomide TMZ 63 Phase #/#a trial 63 investigational humanized monoclonal antibody 63 Th2 cytokines 63 histological subtypes 63 bactericidal activity 63 irinotecan chemotherapy 63 MDA MB 63 gene amplification 63 angiogenesis inhibitor 63 EndoTAGTM 1 63 GW# [003] 63 Thalomid ® 63 gamma tocotrienol 63 JAK1 63 HMG CoA reductase inhibitors 63 matrix metalloproteinases 63 Azedra 63 Lodamin 63 Irinotecan 63 nanomolar range 63 invasive ductal 63 immunohistochemical analysis 63 mRCC 63 IL #E 63 oncoproteins 63 potent anticancer 63 Pegylated 63 Overexpression 63 FUS1 63 inducible nitric oxide synthase 63 vimentin 63 selective orally bioavailable 63 bortezomib 63 homodimers 63 xenograft mouse 63 receptor subtypes 63 HER2/neu 63 antibody mediated 63 tumor vascular disrupting 63 ESBA# 63 pharmacodynamic biomarkers 63 metaglidasen 63 RNA antagonist 63 NS#/#A protease 63 Darinaparsin 63 redox active 63 TACE 63 microRNA miR 63 rituximab Rituxan 63 EGFR tyrosine kinase inhibitor 63 adrenocortical 63 small molecule activators 63 orally dosed 63 anticancer treatments 63 EGFr expressing metastatic colorectal 63 FGFR4 63 NKG2D 63 gastrin 63 anti angiogenic agents 63 humanized monoclonal 63 Fas ligand 63 miR #a [001] 63 Camptosar ® irinotecan 63 p# Shc 63 5 HT2A serotonin 63 camptothecin 63 neutralizing antibody 63 radezolid 63 KRAS wild 63 taxane chemotherapy 63 immunological responses 63 Hsp# inhibitors 63 transfected cells 63 basal cell carcinoma BCC 63 imatinib resistance 63 sunitinib Sutent 63 bladder ovarian 63 compound AEZS 63 fluvastatin 63 PSN# [002] 63 immunofluorescence staining 63 oral bioavailability 63 delta isoform 63 VAPRISOL 63 tubulin polymerization 63 intratumoral 63 antiandrogen 63 CD8 + cytotoxic 63 JAK2 inhibitor 63 EphA2 63 FOLFOX6 63 chemotherapeutics 63 HER3 63 amrubicin 63 bicalutamide 63 Antigen Specific 63 mouse xenograft 63 ErbB1 63 ZACTIMA 63 histone deacetylase inhibitors 63 Tyrima 63 miRNA expression 63 interferon γ 63 targets EpCAM expressing 63 IL #p# 63 Ceplene/IL-2 63 somatostatin analogue 63 immunomodulatory effects 63 Akt inhibitor 63 R Saizen R 63 tumors GIST 63 TKI therapy 63 matrix metalloproteases 63 TGF alpha 63 Anticalins ® 63 Annexin V 63 DOXIL 63 JAK2 63 cleavable linker 63 5 Fluorouracil 63 EGF receptors 63 pharmacokinetic properties 63 peptide conjugated 63 fibrotic disease 63 isotype 63 Temsirolimus 63 monocyte chemotactic protein 63 antimetabolite 63 Akt activation 63 Squalamine 63 AZT zidovudine Retrovir 63 immunoregulatory 63 genotypic resistance 63 fulvestrant 63 serous ovarian cancer 63 miR #a [002] 63 Aplidin R 63 NF kappaB activation 63 FasL 63 cells transfected 63 superficial bladder cancer 63 peritoneal carcinomatosis 63 cediranib 63 relapsed acute myelogenous 63 davunetide intranasal AL 63 antiviral activity 63 castrate resistant 63 liposomal amphotericin B 63 ALB # 63 EGFR receptor 63 antiviral efficacy 63 Azacitidine 63 DiLA2 63 ADP receptor antagonist 63 neuropilin 63 humanised monoclonal antibody 63 alkylating 63 baseline LDH 63 novel topoisomerase 63 Virulizin ® 63 docetaxel Taxotere R 63 tumorigenic 63 small molecule agonists 63 tumor antigen 63 immunomodulatory therapy 63 small molecule tyrosine 63 TIMP 63 myeloablative 63 small molecule defensin 63 apoptosis inducing 63 colorectal carcinomas 63 Pathway Inhibitor 63 metastatic RCC 63 IGFBP 3 63 immunomodulatory properties 63 oral antidiabetic 63 HER2 receptor 63 alkaline phosphatase ALP 63 receptor blocker 63 Fludarabine 63 transgenic rats 63 stem cell pluripotency 63 PEGylated anti 63 prognostic biomarker 63 NMDA antagonist 63 highly selective inhibitor 63 enzyme inhibitor 63 MAb 63 adipogenic 63 CDDO Im 63 cyclophilin inhibitor 63 Panzem R 63 renal cortical 63 MGCD# [001] 63 papillomas 63 nucleosides 63 DermaVir Patch 63 Tumor Response 63 KSP inhibitors 63 p# subunit 63 Traficet EN 63 PKCi 63 miRNAs miR 63 cell adhesion molecule 63 CBLC# 63 thrombopoietin 63 tegafur 63 direct thrombin inhibitors 63 VDAs 63 neutropenia dehydration dyspnea 63 transfection efficiency 63 Bortezomib 63 PD LID 63 Alfacell proprietary ribonuclease 63 pancreatic lung 63 XmAb# 63 HLA DR 63 circulating endothelial cells 63 anti inflammatory cytokine 63 Nilotinib 63 polymerase inhibitors 63 interferon alfa 63 neurite outgrowth 63 cytarabine daunorubicin 63 PROSTVAC VF 63 chemopreventive agents 63 immunohistochemical 63 muscarinic 63 mitomycin 63 antifolates 63 Liposomal 63 LRP5 63 monoclonal anti 63 CYP#A# CYP#D# 63 intravesical 63 chemopreventive agent 63 isoform selective 63 tiuxetan 63 Presents Preclinical Data 63 selectively inhibited 63 Gastrointestinal Stromal Tumors 63 Granulocyte Colony Stimulating Factor 63 gamma secretase inhibitor 63 concurrent chemoradiation 63 Vandetanib 63 T#I mutant 63 Triapine R 63 EGFR pathway 63 KRAS mutations occur 63 #T# L1 63 DAVANAT 63 hormone receptor negative 63 pharmacokinetic characteristics 63 inhibitor RG# 63 BCG refractory 63 Ii protein 63 posaconazole 63 biologic DMARD 63 radiolabeled TM# 63 HBx 63 entinostat 63 cathepsins 63 ceftazidime 63 EndoTAG TM -1 63 γ secretase 63 chemoresistant 63 Gemcitabine 63 carcinoma HCC 63 downregulation 63 TOP2A 63 renal tumors 63 Tumor Necrosis Factor 63 chemotherapeutic agent 63 gemcitabine 63 anti CTLA 63 goserelin 63 HER2 expression 63 IGF1R 63 liposome formulation 63 humoral immunity 63 effector functions 63 EGFR TKI 63 6 mercaptopurine 63 humanized anti 63 murine models 63 caspofungin 63 Cathepsin B 63 glycosylation profile 63 TLR8 agonist 63 panitumumab Vectibix 63 BCR ABL 63 Pegylated Interferon 63 polymerase inhibitor 63 immunoconjugate 63 Aflibercept 63 ABCB1 63 BMS# 63 Camptosar ® 63 JAK3 63 tumor biopsies 63 R lenalidomide 63 pDC 63 IMA# 63 humoral antibody 63 neuroprotective properties 63 targeted radiotherapeutic 63 HCT# 63 thymidylate synthase TS 63 Bcr Abl mutations 63 hepatocellular carcinoma HCC